**Author details**

Chieh-Hsi Wu1 \*, Chun-Hsu Pan1 and Ming-Jyh Sheu<sup>2</sup>

1 School of Pharmacy, Taipei Medical University, Taipei, Taiwan

2 School of Pharmacy, China Medical University, Taichung, Taiwan

\*Address all correspondence to: chhswu@tmu.edu.tw

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**81**

*Therapeutic Applications and Mechanisms of YC-1: A Soluble Guanylate Cyclase Stimulator*

[8] Janssens SP, Simouchi A, Quertermous T, Bloch DB, Bloch KD. Cloning and expression of a cDNA encoding human endothelium-derived relating factor/nitric oxide synthase. Journal of Biological Chemistry.

[9] Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal

failure. Lancet. 1992;**339**:572-575. DOI:

[11] Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clinical and Experimental Nephrology.

2007;**11**:115-121. DOI: 10.1007/

[12] Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Bioscience Reports. 1999;**19**:133-154. DOI: 10.1023/A:1020265417394

[13] Bian K, Murad F. Nitric oxide (NO)—Biogeneration, regulation, and relevance to human diseases. Frontiers in Bioscience. 2003;**8**:d264-d278. DOI:

[14] Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. New England Journal of Medicine. 2006;**355**:2003-2011.

[15] Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases:

DOI: 10.1056/NEJMsa063904

s10157-007-0471-x

10.2741/997

1992;**267**:22694

0140-6736(92)90865-Z

[10] Cooke JP. Does ADMA cause endothelial dysfunction? Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;**20**:2032-2037. DOI: 10.1161/01.ATV.20.9.2032

*DOI: http://dx.doi.org/10.5772/intechopen.84572*

[1] Martin E, Davis K, Bian K, Lee YC, Murad F. Cellular signaling with nitric oxide and cyclic guanosine monophosphate. Seminars in Perinatology. 2000;**24**:2-6. DOI: 10.1016/S0146-0005(00)80045-2

**References**

[2] Murad F. Nitric oxide signaling: Would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Recent Progress in Hormone Research.

1998;**53**:43-59. discussion 59-60

identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells. Journal of Biological Chemistry.

1982;**257**:10147-10151

science.2432665

[3] Deguchi T, Yoshioka M. L-Arginine

[4] Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science. 1987;**235**:473-476. DOI: 10.1126/

[5] Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proceedings of the National Academy of Sciences of the United States

of America. 2001;**98**:4202-4208. DOI: 10.1073/pnas.071054698

[6] Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles

cytochrome P-450 reductase. Nature. 1991;**351**:714-718. DOI:

[7] Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls, and controls. Cell. 1994;**78**:915-918. DOI:

0092-8674(94)90266-6

10.1038/351714a0

*Therapeutic Applications and Mechanisms of YC-1: A Soluble Guanylate Cyclase Stimulator DOI: http://dx.doi.org/10.5772/intechopen.84572*
